Hypoxia and Medicine

Hypoxia Symptoms News

A possible role for Smurf1 in pulmonary arterial hypertensionMonday, June 21, 2010 @ 11:53AMPulmonary arterial hypertension (PAH) is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall, obliteration of the lumen and right heart failure.

A possible role for Smurf1 in pulmonary arterial hypertensionMonday, June 21, 2010 @ 10:47AM( Society for Experimental Biology and Medicine ) Pulmonary arterial hypertension is a progressive disease, marked by shortness of breath and fatigue which can be fatal if untreated. Increased pressure in the pulmonary artery and its branches is associated with dysfunctional growth control of endothelial and smooth muscle cells leading to excessive thickening of the blood vessel wall ...

Genzyme Receives FDA Approval for Lumizyme for Pompe DiseaseTuesday, May 25, 2010 @ 10:06AMCAMBRIDGE, Mass.----Genzyme Corporation announced today that the FDA has granted U.S. marketing approval for Lumizyme™ , produced at the 4000 liter bioreactor scale at its manufacturing facility in Geel, Belgium.

Exelixis Reports Encouraging Interim Data from an Ongoing Adaptive Randomized Discontinuation Trial of XL184 in ...Thursday, May 20, 2010 @ 6:45PMExelixis, Inc. (NASDAQ:EXEL) today reported interim data from an ongoing adaptive randomized discontinuation trial (RDT) of single agent XL184 in ...

Exelixis Reports Encouraging Interim Data from an Ongoing Adaptive Randomized Discontinuation Trial of XL184 in ...Thursday, May 20, 2010 @ 6:35PMSOUTH SAN FRANCISCO, Calif.----Exelixis, Inc. today reported interim data from an ongoing adaptive randomized discontinuation trial of single agent XL184 in patients with melanoma, non-small cell lung cancer , small cell lung cancer , hepatocellular carcinoma , pancreatic, gastric/GE junctional, prostate, ovarian, or breast cancer who have measurable disease and had undergone up to 3 prior lines ...